Management of Overweight and Obese People with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide: A Systematic Review
1. Department of Pharmacy, The People’s Hospital of Jianyang City, Chengdu 641400, China
2. Department of Radiology, The People’s Hospital of Jianyang City, Chengdu 641400, China
| Abstract: | Purpose Aimed to comprehensively investigate the efficacy and safety of the dual GIP/GLP-1 re-ceptor agonist Tirzepatide on overweight and obesity. Methods Embase, PubMed/Medline, Web of Science, Cochrane, CNKI, Wanfang and VIP databases were searched using standard key-words to identify all controlled trials investigating the weight loss effects of Tirzepatide. RevMan 5.3 was used for analysis. Results Eleven randomized controlled trials with 11710 participants were included in this systematic review and meta-regression analysis. The pooled findings showed that Tirzepatide vs control significantly reduced body weight (mean difference (MD): -7.38, 95% confidence interval (CI): -13.66 to -1.09, P=0.02). The results of subgroup analysis showed that the trend of weight loss is dose-dependent (5mg: MD: -6.87, 95%CI: -10.29 to -3.45, P<0.0001; 10 mg: MD: -9.62, 95%CI: -13.11 to -6.13, P<0.000 01; 15mg: MD: -11.00, 95%CI: -14.29 to -7.70, P<0.000 01). HbA1c (MD: -1.38, 95% CI: -1.52 to -1.23, P<0.000 01). The total incidence of adverse reactions in Tirzepatide vs control was significantly increased (Odds Ratio (OR): 1.57, 95%CI: 1.35 to 1.81, P<0.000 01), and these adverse reactions were even greater, especially with higher doses and duration of Tirzepatide. Conclusions The administration of Tirzepatide medication has demonstrated noteworthy effects on weight management, resulting in reductions in both body weight and HbA1c levels. These effects may potentially be dependent on the dosage administered. Consequently, for individuals with diabetes who experience significant impacts on body weight, the utilization of Tirzepatide can be regarded as a viable therapeutic approach for obese individuals. |
| Keywords: | Tirzepatide; The Dual GIP/GLP-1 Receptor Agonist; Efficacy; Safety; Systematic Review |
| DOI: | 10.57237/j.cmf.2026.01.001 |
View:
Downloads:
收稿日期: 2025-06-15
接受日期: 2025-09-08
在线出版日期: 2026-01-14
基金
| 1. | This work was financially supported by grants from the Foundation of the People’s Hospital of Jianyang (JYk202406) |
参考文献
| [1] | Wang, Y.; Zhao, L.; Gao, L.; Pan, A.; Xue, H., Health policy and public health implications of obesity in China. The Lancet Diabetes & Endocrinology 2021, 9, (7), 446-461. |
| [2] | Kow, L.; Sharaiha, R. Z.; O’Kane, M.; White, K. P.; Macedo, G.; Toouli, J.; Shikora, S., Methodology and Results of a Joint IFSO-WGO Delphi Survey of 94 Intercontinental, Interdisciplinary Experts in Obesity Management. Obesity Surgery 2023, 33, (11), 3337-3352. |
| [3] | Salminen, P.; Kow, L.; Aminian, A.; Kaplan, L. M.; Nimeri, A.; Prager, G.; Behrens, E.; White, K. P.; Shikora, S., IFSO Consensus on Definitions and Clinical Practice Guidelines for Obesity Management—an International Delphi Study. Obesity Surgery 2023. |
| [4] | Sun, X.; Yan, A. F.; Shi, Z.; Zhao, B.; Yan, N.; Li, K.; Gao, L.; Xue, H.; Peng, W.; Cheskin, L. J.; Wang, Y., Health consequences of obesity and projected future obesity health burden in China. Obesity 2022, 30, (9), 1724-1751. |
| [5] | Lazzaroni, E.; Ben Nasr, M.; Loretelli, C.; Pastore, I.; Plebani, L.; Lunati, M. E.; Vallone, L.; Bolla, A. M.; Rossi, A.; Montefusco, L.; Ippolito, E.; Berra, C.; D’Addio, F.; Zuccotti, G. V.; Fiorina, P., Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacological research 2021, 171. |
| [6] | Jastreboff, A. M.; Aronne, L. J.; Ahmad, N. N.; Wharton, S.; Connery, L.; Alves, B.; Kiyosue, A.; Zhang, S.; Liu, B.; Bunck, M. C.; Stefanski, A., Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 2022, 387, (3), 205-216. |
| [7] | Rohani, P.; Malekpour Alamdari, N.; Bagheri, S. E.; Hekmatdoost, A.; Sohouli, M. H., The effects of subcutaneous Tir-zepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials. Frontiers in Endocrinology 2023, 14. |
| [8] | Gribble, F. M.; Reimann, F., Metabolic Messengers: glucagon-like peptide 1. Nature Metabolism 2021, 3, (2), 142-148. |
| [9] | Wang, L., Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP. Drug design, development and therapy 2022, Volume 16, 1547-1559. |
| [10] | Dahl, D.; Onishi, Y.; Norwood, P.; Huh, R.; Bray, R.; Patel, H.; Rodríguez, Á., Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes. Jama 2022, 327, (6). |
| [11] | Del Prato, S.; Kahn, S. E.; Pavo, I.; Weerakkody, G. J.; Yang, Z.; Doupis, J.; Aizenberg, D.; Wynne, A. G.; Riesmeyer, J. S.; Heine, R. J.; Wiese, R. J.; Ahmann, A. J.; Arora, S., Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, mul-ticentre, phase 3 trial. The Lancet 2021, 398, (10313), 1811-1824. |
| [12] | Frías, J. P.; Davies, M. J.; Rosenstock, J.; Pérez Manghi, F. C.; Fernández Landó, L.; Bergman, B. K.; Liu, B.; Cui, X.; Brown, K., Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine 2021, 385, (6), 503-515. |
| [13] | Frias, J. P.; Nauck, M. A.; Van, J.; Benson, C.; Bray, R.; Cui, X.; Milicevic, Z.; Urva, S.; Haupt, A.; Robins, D. A., Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, Obesity and Metabolism 2020, 22, (6), 938-946. |
| [14] | Frias, J. P.; Nauck, M. A.; Van, J.; Kutner, M. E.; Cui, X.; Benson, C.; Urva, S.; Gimeno, R. E.; Milicevic, Z.; Robins, D.; Haupt, A., Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a ran-domised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet 2018, 392, (10160), 2180-2193. |
| [15] | Gao, L.; Lee, B. W.; Chawla, M.; Kim, J.; Huo, L.; Du, L.; Huang, Y.; Ji, L., Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nature Medicine 2023, 29, (6), 1500-1510. |
| [16] | Garvey, W. T.; Frias, J. P.; Jastreboff, A. M.; le Roux, C. W.; Sattar, N.; Aizenberg, D.; Mao, H.; Zhang, S.; Ahmad, N. N.; Bunck, M. C.; Benabbad, I.; Zhang, X. M.; Abalos, F. H.; Manghi, F. C. P.; Zaidman, C. J.; Vico, M. L.; Aizenberg, D.; Costanzo, P. R.; Serra, L. P.; Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, ran-domised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402, (10402), 613-626. |
| [17] | Inagaki, N.; Takeuchi, M.; Oura, T.; Imaoka, T.; Seino, Y., Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. The Lancet Diabetes & Endocrinology 2022, 10, (9), 623-633. |
| [18] | Ludvik, B.; Giorgino, F.; Jódar, E.; Frias, J. P.; Fernández Landó, L.; Brown, K.; Bray, R.; Rodríguez, Á., Once-weekly tir-zepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet 2021, 398, (10300), 583-598. |
| [19] | Rosenstock, J.; Wysham, C.; Frías, J. P.; Kaneko, S.; Lee, C. J.; Fernández Landó, L.; Mao, H.; Cui, X.; Karanikas, C. A.; Thieu, V. T., Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SUR-PASS-1): a double-blind, randomised, phase 3 trial. The Lancet 2021, 398, (10295), 143-155. |
| [20] | Pirro, V.; Roth, K. D.; Lin, Y.; Willency, J. A.; Milligan, P. L.; Wilson, J. M.; Ruotolo, G.; Haupt, A.; Newgard, C. B.; Duffin, K. L., Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 2022, 107, (2), 363-378. |
| [21] | Pratley, R. E.; Catarig, A. M.; Lingvay, I.; Viljoen, A.; Paine, A.; Lawson, J.; Chubb, B.; Gorst-Rasmussen, A.; Miresashvili, N., An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes, Obesity and Metabolism 2021, 23, (11), 2513-2520. |
| [22] | Urva, S.; Quinlan, T.; Landry, J.; Martin, J.; Loghin, C., Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics 2021, 60, (8), 1049-1059. |
